'Promising' Leukaemia study to boost patients
Chief investigator Professor Alan Burnett, from Cardiff Universitys School of Medicine, commented on the findings:
These promising results demonstrate how targeting a protein present in more than 90 per cent of AML patients can boost treatment without excessively increasing side effects.
Although there has been some controversy around the use of GO following its withdrawal in the US two years ago, these results appear extremely promising and suggest no such cause for concern if the appropriate dose is given. Crucially, this represents some of the first progress in treating AML patients of this age group for at least 20 years.
More top news
Viewers' guide to the Eurovision Song Contest 2013
Your definitive viewing guide to the 58th annual Eurovision Song Contest in the Swedish city of Malmö.
'We Are Young' by Fun named the most streamed song
We Are Young by Fun Ft Janelle Monae has been named the most streamed song of the year.
Bonnie Tyler to represent UK at Eurovision Song Contest
Bookmakers have given the Neath-born singer odds of 40-1 to win the contest, which will take place in Sweden.